A ccurate measurement of blood pressure (BP) is an essential feature of any trial aiming to determine the relationship between BP reduction and outcome. BP control was the source of a controversy surrounding the results of the Heart Outcomes Prevention Evaluation (HOPE) trial, which claimed additional benefits from the use of an angiotensin-converting enzyme inhibitor (ramipril) versus placebo, because the between-group difference in clinic BP (CBP) was only 3/2 mm Hg.
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In this article, we describe an analysis of the Hypertension in the Very Elderly Trial (HYVET) ABP substudy in which ABP was measured at baseline and on treatment in subgroups of patients in both the active treatment and placebo arms. The between-group difference in BP was determined in the subgroup, and the comparison of ABP and CBP data was also used to determine the extent of WCH in HYVET participants.
Methods
The protocol for ABP monitoring in HYVET has been published elsewhere, 7 as has the protocol for the main study (registered trial number NCT00122811) 8 and the main results. 9 Participants were eligible for the trial if they were aged >80 years and had an average systolic CBP of 160 to 199 mm Hg after at least a 2-month placebo run-in and an average standing systolic CBP of ≥140 mm Hg. At the start of the trial, the participants had to have a diastolic CBP of 90 to 109 mm Hg, although this criterion was later relaxed to allow the inclusion of subjects with isolated systolic hypertension and diastolic CBP <90 mm Hg. Treatment was started with indapamide sustained release (SR) 1.5 mg daily or matching placebo, to which could be added perindopril 2 or 4 mg daily (or matching placebo) to achieve a goal of systolic CBP <150 mm Hg and diastolic CBP <80 mm Hg.
It was planned to recruit 600 patients into the ABP substudy with data both at baseline and during the double-blind phase of the trial. Unfortunately, this was not achieved, though 284 were recruited. Of these, 36 were excluded for the following reasons: 11 recorded <60% of possible ambulatory readings 7 ; 3 were studied while no longer on trial medication; and 1 was excluded because of uncontrolled atrial tachycardia. For baseline measurements, 7 were excluded because they were studied within 7 days of starting placebo run-in and were previously on antihypertensive treatment; and 14 were studied after randomization and may have started trial medication. This left 248 patients in the substudy (112 studied at baseline and 186 on treatment), of whom 50 had both untreated baseline and on-treatment readings. We determined the presence of WCH only at baseline and therefore only evaluated 112 participants in this respect.
Daytime ambulatory readings were those recorded between 8:00 am and 8:00 pm. (The time 8:00 pm was chosen because some very elderly participants retire to bed early.) Night-time readings were those recorded between 10:00 pm and 6:00 am. (The time 6.00 am was chosen in view of the tendency in the very elderly to sleep a shorter number of hours.) Comparisons were made between CBP and daytime ABP and also between CBP and morning ABP readings (between 8:00 am and 12:00 noon) because 90% of centers measured CBP in the morning. ABP readings were recorded by a validated Diasys Integra II ABP recording machine. 10, 11 This machine recorded auscultatory readings if possible and oscillometric readings when an auscultatory reading was not satisfactory. Auscultatory readings were recorded in 86% of instances. The Diasys Integra II also measures arterial compliance using the Q wave (ECG)-Korotkoff diastolic time interval, 12 the results of which will be the subject of a separate publication.
WCH was defined as a systolic CBP ≥140 mm Hg (achieved by all participants) and a daytime ABP of <135 mm Hg systolic and <85 mm Hg diastolic pressure.
13,14
Results
The baseline characteristics of the patients in the ABP substudy were similar to those of the whole HYVET trial ( Table 1) .
The overall CBP and baseline ABP results are presented in Table 2 for both systolic and diastolic pressure. At baseline, the average 24-hour ABP reading was 133/77 mm Hg and the average ABP night-time reading was low at 124/72 mm Hg. The difference between CBP and daytime (8:00 am to 8:00 pm) ABP averaged 36 mm Hg (range −13 to +73 mm Hg) systolic and 12 mm Hg (range −31 to +35 mm Hg) diastolic. Almost all (97%) of patients had systolic CBP greater than daytime ABP ( Figure A) and 80% had diastolic CBP greater than daytime ABP ( Figure B) . When CBP was compared with morning (8:00 am to 12:00 noon) ABP, the average difference was 32 mm Hg (range −33 to +80 mm Hg) systolic and 10 mm Hg (range −35 to +41 mm Hg) diastolic. Ninety percent of patients had systolic CBP greater than morning ABP, and 76% had diastolic CBP greater than morning ABP. WCH at baseline was present in 56 (50%; 95% CI, 40%-60%) participants based on daytime ABP and in 43 (38%; 95% CI, 29%-48%) participants based on morning ABP. There were too few events in the HYVET ABP substudy to determine mortality and morbidity in the 2 treatment groups according to ABP level. Table 3 gives the ABP results according to treatment arm, active treatment (indapamide SR-based) or placebo, with recordings after an average of 13 months on treatment or placebo. The placebo-active treatment difference in daytime ABP was 8 mm Hg systolic and 6 mm Hg diastolic, and the treatment difference in morning ABP was 6 mm Hg systolic and 5 mm Hg diastolic. The 24-hour ABP difference averaged 8/5 mm Hg.
Discussion
The results of the main HYVET study demonstrated that active BP lowering with indapamide±perindopril was associated with a 21% reduction in total mortality, a 30% reduction in stroke, and a 34% reduction in any cardiovascular event.
9 These results applied to trial participants over 80 years of age with an untreated systolic CBP of 160 to 199 mm Hg and a CBP difference of 15/6 mm Hg between the placebo and actively treated groups after 2 years. 9 The ABP side study found a similar difference in CBP between the groups of 17/7 mm Hg at 13 months with a placebo-active difference in 24-hour ABP of 8/5 mm Hg.
The ABP side study suggests that between 40% and 60% of eligible participants in the main study may have had WCH. If WCH does not require treatment it would be surprising that the benefits of treatment were so great. Definitions of systolic hypertension based on daytime ABP range from >135 to >140 mm Hg with night-time ABP >120 mm Hg to >125 mm Hg, [13] [14] [15] [16] and because we found an average baseline daytime systolic ABP of 136 mm Hg and an average night-time systolic of 124 mm Hg, about half of HYVET participants would be judged to have hypertension on ABP criteria. However, it has long been recognized that the CBP-ABP difference increases with age, 4, 5, 17 so that ABP falls with age relative to CBP, leading to our finding that the very elderly have hypertension as determined by CBP but not necessarily when assessed by ambulatory blood pressure monitoring. With the widening gap between CBP and ABP with advancing age, the 2 arbitrary definitions of hypertension diverge, and it is unlikely that the present definition of WCH is appropriate over 80 years of age. Indeed, it is recognized that the prevalence of WCH increases with age, [17] [18] [19] [20] [21] and the possibility remains that many with this condition would benefit from treatment. A recent database analysis reported a 28.6% prevalence of WCH in subjects with isolated systolic hypertension and an average of 60 years of age. In untreated subjects, those with WCH and subjects with a normal BP were at a similar risk (P=0.29). However, the authors commented "our subgroup analysis suggests that men and diabetics with untreated White-Coat Hypertension are at increased risk." 22 One potential subgroup will be the very elderly, and ABP may be considerably lowered by active treatment in those with WCH. We suggest that WCH may need active treatment in the very elderly or the definition of WCH needs to be changed for this age group. However, a randomized trial specifically in subjects with WCH is needed to inform this debate. We must bear in mind that systolic pressure drives the prediction of morbidity and mortality in the elderly, and also that other measures, such as home BP measurements, may prove successful in detecting WCH.
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It is also not widely recognized that an elderly group with an average night-time systolic ABP of 124 mm Hg would have such dramatic benefits from BP lowering, but this is true in the main trial. 9 In addition, a low average night-time pressure corresponding to a systolic CBP ≥160 mm Hg has been recorded in younger elderly subjects in the Systolic HypertensionEurope (SYST-EUR) trial, namely 134 mm Hg. 23 In this trial, it was concluded that the benefit of antihypertensive therapy is less evident when daytime systolic ABP is ≤160 mm Hg, 6 but it cannot be excluded that treatment of WCH would also be beneficial in the younger elderly.
The treatment effect on 24-hour ABP of 8/5 mm Hg confirms the 24-hour BP-lowering efficacy of indapamide SR 1.5 mg± perindopril 2 to 4 mg daily. ABP treatment differences usually agree well with the result from clinic measures, and treatment was effective when measured by both methods. [26] [27] [28] The difference between the groups was 8/4 mm Hg for night-time ABP and even higher in the 52 participants with ABP measurements at baseline and during follow-up (online-only Data Supplement). Over 65 years of age, night-time ABP is a better predictor of cardiovascular events than the CBP and other measures of ABP. 29, 30 Burr et al 18 studied a population of average age 73 years (range 65-92 years) and average night-time systolic BP of 133 mm Hg, and found a hazard ratio for cardiovascular mortality of 1.18 for every 10 mm Hg increase in night-time systolic ABP unadjusted for CBP. Thus, untreated, our participants on placebo with an excess of 8 mm Hg night-time systolic pressure over the actively treated group would have been expected to have an excess of 14.4% in cardiovascular mortality compared with actively treated subjects. An excess of 23% was observed for cardiovascular mortality in the HYVET trial placebo group (unadjusted for CBP), 9 indicating a fair agreement with that expected. The predictions of Burr et al 18 for an increase in cardiovascular mortality of 1.09 for every 5 mm Hg increase in night-time diastolic BP (1.08 for 24-hour diastolic BP) would suggest an excess of 7.2% in cardiovascular mortality in the placebo group (arising from the placebo-active difference of 4 mm Hg), which is much lower than that actually observed. 9 However, the actual difference in ambulatory diastolic pressure may be greater (Table S4) , and other trials in the elderly, such as the European Working Party on High Blood Pressure in the Elderly (EWPHE) 31 and SYST-EUR, 25 have also reported that excess mortality is driven by systolic rather than diastolic BP. Moreover, the HYVET study recruited only older participants with systolic CBP 160 to 199 mm Hg untreated, whereas Burr et al 18 included a wide range of ages (65-92 years) and systolic CBPs (mean±SD, 172±26.8 mm Hg).
Interestingly, results from an international database 30 suggest that daytime pressure is a better predictor of cardiac events than night-time pressure, the latter being more important for stroke events. Stroke events far outweighed cardiac events in the HYVET study. However, others have suggested that nighttime ABP is also a better predictor of cardiac events. 32 Untreated morning ABP averaged 140/80 mm Hg, daytime pressure 136/78 mm Hg, and night-time pressure The limitations of this ABP substudy in HYVET include the small number of participants studied and the failure to consistently provide follow-up readings.
There were only 52 subjects with both baseline and followup visits, and these participants may not have been representative of those in the main trial. Their data are presented in the online-only Data Supplement. Nevertheless, the estimate of the placebo-active treatment 24-hour BP difference for the whole subgroup at follow-up (8/5 mm Hg) was in line with the clinic difference for the whole of the subgroup (17/7 mm Hg). The characteristics of the participants studied were similar to those in the trial as a whole, and the results showed the expected and consistent differences among morning, afternoon, and night-time measurements. Another limitation is that the number of participants was too low to differentiate results for indapamide alone or in combination with the 2 doses of perindopril (35% of participants on active treatment in the substudy were on combined treatment).
One strength of the study was the use of the Diasys Integra II, which also provided the compliance measures of Q wave (ECG)-Korotkoff diastolic. The results of these measurements are expected to give more complete information on the effects of indapamide SR±perindopril. In the present communication, we confined the results to morning, afternoon, daytime, nighttime, and 24-hour measures of ABP. Too few subjects were included in the substudy to attempt to assess the predictive value of ABP over and above CBP.
Perspectives
The increasing divergence between CBP and ABP in the very elderly, in the presence of marked benefits from treatment based on indapamide SR±perindopril, indicates that WCH may not be a benign condition in the elderly, and that it would be very dangerous to limit the definition of systolic hypertension to a 24-hour systolic ABP of >135 mm Hg or even 130 mm Hg. 15 Our data suggest that a systolic 24-hour ABP of ≥125 mm Hg may require treatment when the subject is >80 years of age. This goes against the recent National Institute for Health and Clinical Excellence guidelines, 34 which advise against treatment of WCH, having defined it by measuring ABP. However, the National Institute for Health and Clinical Excellence guideline agrees with the meta-analyses of studies in younger subjects with an average age of 56 to 63 years, where WCH had a hazard rate compared with normotension of only 1.12 (95% CI, 0.84-1.50), 35 1.17 (0.87-1.57), 22 and 1.22 (0.96-1.53) 36 for cardiovascular events. 34 The National Institute for Health and Clinical Excellence guidelines may be correct for younger subjects but may not be for those aged >80 years. A randomized trial is required to further this debate. It must also be remembered that participants with a standing systolic CBP of <140 mm Hg were excluded from the trial. Thus, when WCH was accompanied by severe orthostatic hypertension or impaired baroreflexes they were excluded from the HYVET trial, and this group may not benefit from active treatment.
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Summary
This study shows that white coat hypertension is common in the >80-year-old patient and this may require treatment. This should be included in national guidelines for treatment of hypertension in the very elderly. Table S1 gives the corresponding results for the 52 participants where WCH status was known at baseline and on-treatment ABP results were available. In those with WCH, ABP tended to rise if given a placebo and to be maintained if given active treatment, to give a 24 hour ABP placebo-active treatment effect of 21/10 mm Hg. In those with sustained BP, ABP tended to be maintained on placebo treatment and to fall on active treatment to give a placebo-active treatment effect of 15/6 mm Hg.
Discussion
In the 52 participants who had both baseline and follow-up ABP measurements, those with WCH had a 24 hour placebo-active blood pressure lowering effect of 21/10 mm Hg and those with sustained BP a difference of 15/6 mm Hg, reinforcing the possibility of a benefit from the active treatment of WCH. The difference between sitting CBP and daytime ABP was higher in the placebo group than in the actively treated group. This was expected as the higher the CBP the greater the potential White Coat effect. Table S1 . Ambulatory blood pressure (ABP) results on placebo and active treatment at an average of 13 months. Clinic blood pressure (CBP) is given for nearest date to ABP readings. The 52 participants who had both baseline and a treatment ABP are divided according to whether that had White Coat Hypertension (WCH) at baseline on a sustained BP and whether they received active on placebo treatment. Mean (standard deviation). 
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